Artificial intelligence (AI) based spatial assessment of tumor-infiltrating lymphocytes (TIL) and pathologic complete response in early HER2+ breast cancer (BC): Secondary analysis of NSABP B-41
551Background: Manual quantitative assessment of stromal TILs has shown promise as a biomarker in HER2+ BC. We present an AI-powered single-cell TIL assessment. Methods: Manual TIL assessment was completed per guidelines. Zero-shot, AI-powered pipeline (Case45) was used to analyze tumor microenviron...
Saved in:
Published in | Journal of clinical oncology Vol. 43; no. 16_suppl; p. 551 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
American Society of Clinical Oncology
01.06.2025
|
Online Access | Get full text |
ISSN | 0732-183X 1527-7755 |
DOI | 10.1200/JCO.2025.43.16_suppl.551 |
Cover
Abstract | 551Background: Manual quantitative assessment of stromal TILs has shown promise as a biomarker in HER2+ BC. We present an AI-powered single-cell TIL assessment. Methods: Manual TIL assessment was completed per guidelines. Zero-shot, AI-powered pipeline (Case45) was used to analyze tumor microenvironment (TME) from H&E slides, focusing on TILs and their spatial interplay with cancer cells. The algorithm identified all cells, deriving three metrics: pct_lymphocyte (lymphocytes/total cells), AI_TIL (adjacent-tumor lymphocyte to stromal cell ratio), hotspot_immune (normalized fraction of immune cell aggregates in relation to cancer/tissue). Spearman correlation coefficients evaluated correlations; logistic regression models assessed the relationship between TIL measurements and pCR, with and without gene expression adjustments. AUC assessed predictive performance, and univariate Cox models examined TILs' association with event-free survival (EFS). Results: Our analyses included tumors of 262 patients with early-stage HER2+ BC, 67% estrogen receptor (ER) positive, 51% positive lymph nodes. Poor histologic grade (p<0.001), non-luminal (p=0.006), and ER- tumors (p=0.003) were associated with higher manual TILs. Manual TILs were moderately associated with pct_lymphocyte (r= 0.34) and AI_TIL (r= 0.43). Perthe table, manual TILs were positively associated with pCR, the association was numerically stronger in ER- tumors (Interaction p=0.38). pct_lymphocyte and AI_TIL were positively associated with pCR, regardless of ER status. hotspot_immune was strongly associated with pCR (OR=1.26 for all, 1.29 in ER-, 1.22 in ER+, p=<0.001). TILs and ESR1 and ERBB2 provided complementary prognostic utility in pCR in trastuzumab-treated patients (AUC: 0.699-0.757). Among all subjects, there was no association between manual TILs and EFS (p=0.2); there was a marginal association between AI_TIL and EFS (p=0.06). Conclusions: The spatial characterization of TILs using an AI-powered tool shows promise as a prognostic biomarker in both HER2+/ER+ and HER2+/ER- BC, manual TIL assessment is prognostic in HER2+/ER- BC. The assessment of immune aggregates appears to be highly predictive of pCR. Further validation through prospective-retrospective studies, focused on the spatial immune heterogeneity in the TME, is required before integrating these biomarkers into routine clinical practice. Clinical trial information: NCT00486668. TILs measurements and pCR.Variable (continuous)CohortOR (95% CI)p-valueManual TILs %(10-unit inc.)All1.13 (1.04, 1.23)0.004ER-1.16 (1.02, 1.31)0.02ER+1.07 (0.95, 1.21)0.27Percentage of Lymphocyte (10-unit inc.)All2.00 (1.30, 3.07)0.002ER-1.75 (0.95, 3.21)0.07ER+1.93 (1.02, 3.62)0.04AI TILs(one-tenth inc.)All1.22 (1.06, 1.40)0.005ER-1.19 (0.98, 1.44)0.09ER+1.19 (0.97, 1.46)0.10 |
---|---|
AbstractList | 551
Background: Manual quantitative assessment of stromal TILs has shown promise as a biomarker in HER2+ BC. We present an AI-powered single-cell TIL assessment. Methods: Manual TIL assessment was completed per guidelines. Zero-shot, AI-powered pipeline (Case45) was used to analyze tumor microenvironment (TME) from H&E slides, focusing on TILs and their spatial interplay with cancer cells. The algorithm identified all cells, deriving three metrics: pct_lymphocyte (lymphocytes/total cells), AI_TIL (adjacent-tumor lymphocyte to stromal cell ratio), hotspot_immune (normalized fraction of immune cell aggregates in relation to cancer/tissue). Spearman correlation coefficients evaluated correlations; logistic regression models assessed the relationship between TIL measurements and pCR, with and without gene expression adjustments. AUC assessed predictive performance, and univariate Cox models examined TILs' association with event-free survival (EFS). Results: Our analyses included tumors of 262 patients with early-stage HER2+ BC, 67% estrogen receptor (ER) positive, 51% positive lymph nodes. Poor histologic grade (p<0.001), non-luminal (p=0.006), and ER- tumors (p=0.003) were associated with higher manual TILs. Manual TILs were moderately associated with pct_lymphocyte (r= 0.34) and AI_TIL (r= 0.43). Perthe table, manual TILs were positively associated with pCR, the association was numerically stronger in ER- tumors (Interaction p=0.38). pct_lymphocyte and AI_TIL were positively associated with pCR, regardless of ER status. hotspot_immune was strongly associated with pCR (OR=1.26 for all, 1.29 in ER-, 1.22 in ER+, p=<0.001). TILs and ESR1 and ERBB2 provided complementary prognostic utility in pCR in trastuzumab-treated patients (AUC: 0.699-0.757). Among all subjects, there was no association between manual TILs and EFS (p=0.2); there was a marginal association between AI_TIL and EFS (p=0.06). Conclusions: The spatial characterization of TILs using an AI-powered tool shows promise as a prognostic biomarker in both HER2+/ER+ and HER2+/ER- BC, manual TIL assessment is prognostic in HER2+/ER- BC. The assessment of immune aggregates appears to be highly predictive of pCR. Further validation through prospective-retrospective studies, focused on the spatial immune heterogeneity in the TME, is required before integrating these biomarkers into routine clinical practice. Clinical trial information: NCT00486668 . TILs measurements and pCR. Variable (continuous) Cohort OR (95% CI) p-value Manual TILs %(10-unit inc.) All 1.13 (1.04, 1.23) 0.004 ER- 1.16 (1.02, 1.31) 0.02 ER+ 1.07 (0.95, 1.21) 0.27 Percentage of Lymphocyte (10-unit inc.) All 2.00 (1.30, 3.07) 0.002 ER- 1.75 (0.95, 3.21) 0.07 ER+ 1.93 (1.02, 3.62) 0.04 AI TILs(one-tenth inc.) All 1.22 (1.06, 1.40) 0.005 ER- 1.19 (0.98, 1.44) 0.09 ER+ 1.19 (0.97, 1.46) 0.10 551Background: Manual quantitative assessment of stromal TILs has shown promise as a biomarker in HER2+ BC. We present an AI-powered single-cell TIL assessment. Methods: Manual TIL assessment was completed per guidelines. Zero-shot, AI-powered pipeline (Case45) was used to analyze tumor microenvironment (TME) from H&E slides, focusing on TILs and their spatial interplay with cancer cells. The algorithm identified all cells, deriving three metrics: pct_lymphocyte (lymphocytes/total cells), AI_TIL (adjacent-tumor lymphocyte to stromal cell ratio), hotspot_immune (normalized fraction of immune cell aggregates in relation to cancer/tissue). Spearman correlation coefficients evaluated correlations; logistic regression models assessed the relationship between TIL measurements and pCR, with and without gene expression adjustments. AUC assessed predictive performance, and univariate Cox models examined TILs' association with event-free survival (EFS). Results: Our analyses included tumors of 262 patients with early-stage HER2+ BC, 67% estrogen receptor (ER) positive, 51% positive lymph nodes. Poor histologic grade (p<0.001), non-luminal (p=0.006), and ER- tumors (p=0.003) were associated with higher manual TILs. Manual TILs were moderately associated with pct_lymphocyte (r= 0.34) and AI_TIL (r= 0.43). Perthe table, manual TILs were positively associated with pCR, the association was numerically stronger in ER- tumors (Interaction p=0.38). pct_lymphocyte and AI_TIL were positively associated with pCR, regardless of ER status. hotspot_immune was strongly associated with pCR (OR=1.26 for all, 1.29 in ER-, 1.22 in ER+, p=<0.001). TILs and ESR1 and ERBB2 provided complementary prognostic utility in pCR in trastuzumab-treated patients (AUC: 0.699-0.757). Among all subjects, there was no association between manual TILs and EFS (p=0.2); there was a marginal association between AI_TIL and EFS (p=0.06). Conclusions: The spatial characterization of TILs using an AI-powered tool shows promise as a prognostic biomarker in both HER2+/ER+ and HER2+/ER- BC, manual TIL assessment is prognostic in HER2+/ER- BC. The assessment of immune aggregates appears to be highly predictive of pCR. Further validation through prospective-retrospective studies, focused on the spatial immune heterogeneity in the TME, is required before integrating these biomarkers into routine clinical practice. Clinical trial information: NCT00486668. TILs measurements and pCR.Variable (continuous)CohortOR (95% CI)p-valueManual TILs %(10-unit inc.)All1.13 (1.04, 1.23)0.004ER-1.16 (1.02, 1.31)0.02ER+1.07 (0.95, 1.21)0.27Percentage of Lymphocyte (10-unit inc.)All2.00 (1.30, 3.07)0.002ER-1.75 (0.95, 3.21)0.07ER+1.93 (1.02, 3.62)0.04AI TILs(one-tenth inc.)All1.22 (1.06, 1.40)0.005ER-1.19 (0.98, 1.44)0.09ER+1.19 (0.97, 1.46)0.10 |
Author | Swain, Sandra M. AbdulJabbar, Khalid Maley, Sai Kumar Hook, Isaac Harris, Brent T. Wolmark, Norman Salgado, Roberto Rastogi, Priya Yan, Haixi Tang, Gong Freeman, Tanner |
Author_xml | – sequence: 1 givenname: Gong surname: Tang fullname: Tang, Gong – sequence: 2 givenname: Khalid surname: AbdulJabbar fullname: AbdulJabbar, Khalid – sequence: 3 givenname: Brent T. surname: Harris fullname: Harris, Brent T. – sequence: 4 givenname: Priya surname: Rastogi fullname: Rastogi, Priya – sequence: 5 givenname: Tanner surname: Freeman fullname: Freeman, Tanner – sequence: 6 givenname: Sai Kumar surname: Maley fullname: Maley, Sai Kumar – sequence: 7 givenname: Haixi surname: Yan fullname: Yan, Haixi – sequence: 8 givenname: Isaac surname: Hook fullname: Hook, Isaac – sequence: 9 givenname: Norman surname: Wolmark fullname: Wolmark, Norman – sequence: 10 givenname: Roberto surname: Salgado fullname: Salgado, Roberto – sequence: 11 givenname: Sandra M. surname: Swain fullname: Swain, Sandra M. |
BookMark | eNqFkc2O0zAQxyO0SHQX3mGOrVCCHcdJiri01cIWVSxiF4mb5TiT1uDYke1qldfjyXC1cOY0Gs38P6TfdXZlncUsA0oKWhLy7vPuvihJyYuKFbQW4TxNpuCcvsgWlJdN3jScX2UL0rAypy378Sq7DuEnIbRqGV9kvzc-6kErLQ1oG9EYfUSrEJab_Qo6GbCHMMl4ucsQMIQRbQQ3QDyPzufaDtpEnx7sEcw8Tien5ogBlo_7wwqk7SGpT864o1ag3DgZjAgew-RswJQJKL2Z4e72W_kWOo8yRFAyVfCw3O5W7-EBlbO99HNyk2YOOlzivzxstl9hm1f0dfZykCbgm7_zJvv-8fZxd5cf7j_td5tDrigpad5RVHWNKOv1upaNLOm64XXfVl1V9WlHztu6Z6RjXcU61ZOBDSXlXTWQjhPG2E3WPvsq70LwOIjJ6zH1EpSICwuRWIgLC1Ex8Y-FSCyS9MOz9MmZiD78Mucn9OKE0sTT_-V_AGhil4I |
ContentType | Journal Article |
Copyright | 2025 by American Society of Clinical Oncology |
Copyright_xml | – notice: 2025 by American Society of Clinical Oncology |
DBID | AAYXX CITATION |
DOI | 10.1200/JCO.2025.43.16_suppl.551 |
DatabaseName | CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1527-7755 |
EndPage | 551 |
ExternalDocumentID | 10_1200_JCO_2025_43_16_suppl_551 486840 |
Genre | meeting-report |
GroupedDBID | --- .55 0R~ 18M 34G 39C 4.4 5GY 5RE 8F7 AAQQT AARDX AAWTL AAYEP ABBLC ABJNI ABOCM ACGFO ACGFS ACGUR ADBBV AEGXH AENEX AIAGR ALMA_UNASSIGNED_HOLDINGS BAWUL BYPQX C45 CS3 DIK EBS EJD F5P F9R FBNNL FD8 GX1 HZ~ IH2 IPNFZ K-O KQ8 L7B LSO MJL N9A O9- OK1 OVD OWW P2P QTD R1G RHI RIG RLZ RUC SJN TEORI TR2 TWZ UDS VVN WH7 X7M YFH YQY .GJ 08G 08P 29K 2WC 3O- 53G 5VS 8WZ A6W AAKAS AAQOH AAYOK AAYXX ADZCM AFFNX AI. ASPBG AVWKF AZFZN CITATION D-I EX3 FEDTE H13 HVGLF J5H N4W NTWIH UHU VH1 WOQ WOW ZGI |
ID | FETCH-LOGICAL-c1021-b1ec66eea6996a7a219756d84b44da7ae5586d30b3b43bcd0f3f215b4f0b50333 |
ISSN | 0732-183X |
IngestDate | Thu Jul 03 08:43:28 EDT 2025 Mon Jun 09 20:30:16 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 16_suppl |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c1021-b1ec66eea6996a7a219756d84b44da7ae5586d30b3b43bcd0f3f215b4f0b50333 |
Notes | Abstract Disclosures |
PageCount | 128 |
ParticipantIDs | crossref_primary_10_1200_JCO_2025_43_16_suppl_551 wolterskluwer_health_10_1200_JCO_2025_43_16_suppl_551 |
PublicationCentury | 2000 |
PublicationDate | 20250601 2025-06-00 |
PublicationDateYYYYMMDD | 2025-06-01 |
PublicationDate_xml | – month: 6 year: 2025 text: 20250601 day: 1 |
PublicationDecade | 2020 |
PublicationTitle | Journal of clinical oncology |
PublicationTitleAbbrev | ASCO MEETING ABSTRACTS |
PublicationYear | 2025 |
Publisher | American Society of Clinical Oncology |
Publisher_xml | – name: American Society of Clinical Oncology |
SSID | ssj0014835 |
Score | 2.4790862 |
Snippet | 551Background: Manual quantitative assessment of stromal TILs has shown promise as a biomarker in HER2+ BC. We present an AI-powered single-cell TIL... 551 Background: Manual quantitative assessment of stromal TILs has shown promise as a biomarker in HER2+ BC. We present an AI-powered single-cell TIL... |
SourceID | crossref wolterskluwer |
SourceType | Index Database Publisher |
StartPage | 551 |
Title | Artificial intelligence (AI) based spatial assessment of tumor-infiltrating lymphocytes (TIL) and pathologic complete response in early HER2+ breast cancer (BC): Secondary analysis of NSABP B-41 |
URI | https://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&DO=10.1200/JCO.2025.43.16_suppl.551 |
Volume | 43 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1db9MwFLW2ISEkhGCAGF-6DzBt6lLaOF-Dp7ZsrNtoC-ukvkWO44yJ0qC0FSo_j1_GvXbSpNoQsJeoSRXb0fWx77XPPWbslS8bMuaesOzY8SzH58IioSLLbyil-L4nVazZFj3v6Nw5HrmjtfV3FdbSfBbV5c9r80puYlV8hnalLNn_sOyyUHyAv9G-eEUL4_WfbNzKNNNHn7tRldZEr7HVpXif5qi4NiXWNGkCLFU4NTNg_i3NLGzG5VhL504uauMF2jaVi3wtdtg9pUK0lICY5cOkIaGjq13LDL3WqI5oneSjg8_2a7tdi4jpPiNCmSSlCjtod7AgWnw4o_g7JqaeqKih9M5a7UGtbRlxqmt85WX-ZjqRK_sAw3y5-0Oaz8B6Jyuej49FFBnu-MkXDDXicqTNMiOr0Na6VMN6udOFfvCFJjcMssuFqK6H2G7J26qkINDYmLNeidVSNLJfbaQZZH1uWzisjcx8mE8Cto9Rh5EPLmYJIyZVoMELp3ToamXkd3PdXFW9uzI_2ebo7U6_Tk2vO7xeFFVfFlCVBO_1w8H7w_C02ztZ_VN7IE5AUj3r7Jbt-5qjcPKp3EJzAnO6bPGBOY0NW_DmT_Wv-GZ3f6TE15h-1ekaFadreJ_dy3sAtEzXf8DW1GST3f6Y80E22fbAKK8v9mBYJhJO92AbBqUm--Ih-1VCBapQgZ1Wdxc0TCCHCZQwgTSBqzCBCkxgB0GyCwgRKCECBUSggAjWCRoiQBCpgQEIGIDATruz-xaW0IACGlS9hgYQNB6x88ODYefIyo8vsWSTiE9RU0nPU0p4-_ue8AX6Br7rxYETOU6M98p1Ay_mjYhHDo9k3Eh4gg545CSNiMgF_DHbmKQT9YRBIrhMhBc0SJtJ8kC4scJ4U_Ik4VL4_hZrFoYLvxuVmpCie5u2qjv9kIwdOjwsjB2isbeYu2Lh0CRe__W9pzd87xm7U8L1OduYZXP1Ah36WfRSd9zf-k76Cw |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Artificial+intelligence+%28AI%29+based+spatial+assessment+of+tumor-infiltrating+lymphocytes+%28TIL%29+and+pathologic+complete+response+in+early+HER2%2B+breast+cancer+%28BC%29%3A+Secondary+analysis+of+NSABP+B-41&rft.jtitle=Journal+of+clinical+oncology&rft.au=Tang%2C+Gong&rft.au=AbdulJabbar%2C+Khalid&rft.au=Harris%2C+Brent+T.&rft.au=Rastogi%2C+Priya&rft.date=2025-06-01&rft.pub=American+Society+of+Clinical+Oncology&rft.issn=0732-183X&rft.eissn=1527-7755&rft.volume=43&rft.issue=16_suppl&rft.spage=551&rft.epage=551&rft_id=info:doi/10.1200%2FJCO.2025.43.16_suppl.551&rft.externalDBID=NO_PDF_LINK&rft.externalDocID=486840 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0732-183X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0732-183X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0732-183X&client=summon |